Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies
Sathish Gopalakrishnan,1 Daryl Tan1,2 1Department of Hematology, Singapore General Hospital, Singapore, Republic of Singapore; 2Raffles Cancer Center, Raffles Hospital, Singapore, Republic of Singapore Abstract: Although the clinical outcomes of patients with multiple myeloma has improved tremendous...
Guardado en:
Autores principales: | Gopalakrishnan S, Tan D |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/73f7face19004ee9bc6bb0fa042fbaf2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
por: Foteini Theodorakakou, et al.
Publicado: (2021) -
HOW I TREAT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS?
por: María-Victoria Mateos
Publicado: (2021) -
INSIGHTS INTO DIAGNOSIS AND MANAGEMENT OF ADVANCED MULTIPLE MYELOMA
por: Vasile Musteata, et al.
Publicado: (2021) -
Profile of elotuzumab and its potential in the treatment of multiple myeloma
por: Liu YC, et al.
Publicado: (2014) -
CASE REPORT: COEXISTENCE OF CELIAC DISEASE AND MULTIPLE MYELOMA
por: Filiz YAVASOGLU, et al.
Publicado: (2021)